Abstract: The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5?-triphosphate and/or at least one 5?-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject.

Abstract: The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises a 5?-triphosphate or a 5?-diphosphate.

Abstract: [Object] To provide a method of producing a plate denture using a stereolithography 3D printer, which is capable of producing a plate denture in a short time with a more simplified production process, the plate denture exhibiting excellent occlusion. [Solving Means] The problem is solved by a method of producing a plate denture, including: adhering an artificial tooth and a denture base photochemically solidified by a stereolithography 3D printer to each other by polymerizing an unpolymerized curable composition for stereolithography present on a surface of the denture base. Further, stronger adhesion between the artificial tooth and the denture base is achieved by mixing, in the curable composition for stereolithography, a polymerization initiator other than a photopolymerization initiator for stereolithography.

Abstract: An optical line terminal includes: one or more optical line termination units to which an optical network unit of an optical communication system is connected, the one or more optical line termination units acquiring an allocation requested bandwidth from the optical network unit connected; a slice management unit that manages slice configuration information indicating which slice each of the optical network unit connected to the optical line termination unit is included in, and manages a limitation on allocation of bandwidth for the optical network unit as a parameter for allocating bandwidth; and a bandwidth allocation unit that determines, for each of the slice, an allocated bandwidth for each of the optical network unit connected to the optical line termination unit on the basis of the allocation requested bandwidth, the slice configuration information, and the parameter for allocating bandwidth.

Abstract: A resource allocation device includes: a required resource calculation unit that calculates, for each slice, a required occupation value and a required share value based on a predicted value and prediction accuracy of traffic generated in each of one or more slices generated between a host pair of a higher device and a lower device, and calculates a total required occupation value and a total required share value on a host pair basis based on the required occupation value and the required share value calculated; and a resource allocation unit that determines, for each host pair, whether the total required occupation value and the total required share value are allowed to be allocated to the host pair based on an available resource, and allocates the required occupation value and the required share value to each slice in a case where the allocation is possible.

Abstract: The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5?-triphosphate and/or at least one 5?-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject.

Abstract: A server device includes a support information generation unit, a condition determination unit, and a resource calculation unit. The support information generation unit generates support information for each support-provided area using information from a communication terminal. The condition determination unit determines a support information generation condition being a condition concerning the support information to be generated by the support information generation unit, based on area situation information representing a situation thereof.

Abstract: Compositions and methods for inducing a protective mucosal immunity against an antigen in a subject include the step of administering to a mucosal tissue an effective amount of a vaccine composition including the antigen or polynucleotide encoding an antigen associated or encapsulated within carriers such as poly(amine-co-ester) polymers in the form of particles (e.g., solid nanoparticles formed of PACE) or PACE copolymers and/or blends. Typically, the subject has previously been exposed to the antigen, for example, by administering to the same subject via a systemic or mucosal route of administration a priming antigen. In some embodiments, the polynucleotides-based vaccines are messenger RNAs encoding a viral antigen such as a coronavirus spike protein sequence, or a portion thereof. In preferred embodiments, the vaccine composition is administered intranasally.

Abstract: The present invention provides combination therapies that are useful for treating and/or preventing certain cancers. In certain embodiments, the therapy comprises an immune-checkpoint inhibitor and a RIG-I agonist. In other embodiments, the therapy comprises a RIG-I agonist.

Abstract: The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5?-triphosphate and/or at least one 5?-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject.

Abstract: To provide a method of producing a plate denture using a stereolithography 3D printer, which is capable of producing a plate denture in a short time with a more simplified production process, the plate denture exhibiting excellent occlusion. [Solving Means] The problem is solved by a method of producing a plate denture, including: adhering an artificial tooth and a denture base photochemically solidified by a stereolithography 3D printer to each other by polymerizing an unpolymerized curable composition for stereolithography present on a surface of the denture base. Further, stronger adhesion between the artificial tooth and the denture base is achieved by mixing, in the curable composition for stereolithography, a polymerization initiator other than a photopolymerization initiator for stereolithography.

Abstract: The present disclosure relates to compositions and methods for treating or preventing a disease or disorder of the brain, spinal cord or central nervous system. It is described herein that an immunogenic composition which induces a CD4 T cell immune response induces permeability of the blood brain barrier, and allows for the access of a therapeutic antibody or agent to the brain, spinal cord or central nervous system.

Abstract: The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5?-triphosphate and/or at least one 5?-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject.

Abstract: An OLT connected with a controller managing slices includes a bandwidth allocating unit capable of allocating bandwidths in a PON system to ONUs through allocation methods, a slice managing unit that calculates a guaranteed delay time for each allocation method, receives, from the controller, a resource reservation request including a bandwidth requested to be reserved in the PON system for a slice and a requested delay time, and determines an allocation method associated with the request based on the requested delay time and the guaranteed delay time for each allocation method, and a resource information generating unit that holds, as abstract resource information, an available bandwidth for the guaranteed delay times of each ONUs, calculates an available bandwidth in the allocation method of the associated ONU based on the allocation method associated with the request and the requested bandwidth, and updates and transmits the abstract resource information, to the controller.

Abstract: A controller that is a resource management device includes: a history information storage unit storing, for each combination of endpoint nodes constituting endpoints of a network and for each type of service, history information indicating used bands previously required for providing a service; a non-used resource calculation unit calculating non-used resource information based on the history information stored corresponding to a first service that is a service already allocated a resource, the non-used resource information indicating a resource that is not used while the first service is provided; and an available resource generation unit generating available resource information based on the non-used resource information, the available resource information indicating an available resource including a shareable resource and available to a second service to be newly provided, the shareable resource being a part, shareable with the second service, of the resource already allocated to the first service.

Abstract: The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5?-triphosphate and/or at least one 5?-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject.

Abstract: The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises a 5?-triphosphate or a 5?-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject.

Abstract: A network control device for generating a slice by dividing a network and allocating communication resources to the slice, the slice being a virtual network, the network control device including: a processor; and a memory to store a program which, when executed by the processor, performs processes of: obtaining and holding resource information from a network device included in the network, the resource information including information on a maximum usage rate of communication resources allocated to a previously generated slice in at least one predetermined period; and determining, upon receiving a request for generating a new slice, whether or not the requested slice can be generated on the basis of the resource information held, wherein the resource information includes information on a maximum usage rate of communication resources, which are allocated to the previously generated slice, depending on a request delay concerning the slice in the predetermined period.

Abstract: A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistemamagna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered.

Abstract: The present disclosure relates to compositions and methods for treating or preventing a disease or disorder of immunoprivileged tissue. It is described herein that an immunogenic composition which induces production of memory CD4 T cells allows for the access of a therapeutic antibody to the immunoprivileged tissue.